Skip to main content

Caplan Jay David's Form 4 filing

Fractyl Health, Inc.GUTS · filed Feb 3, 2025

Accession no.
0000950170-25-012530
Filed
Feb 3, 2025
Trade date
Jan 30-31, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $82.3K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Caplan Jay DavidCIK 0001419217Officer (President, Chief Product Off.)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 30, 2025Common StockMOption exerciseAcquired+21,472$1.70+$36,502.4175,016Direct
Jan 30, 2025Common StockSSaleDisposed−21,472$1.95F2−$41,870.4153,544Direct
Jan 31, 2025Common StockMOption exerciseAcquired+22,346$1.70+$37,988.2175,890Direct
Jan 31, 2025Common StockSSaleDisposed−22,346$1.81F3−$40,446.26153,544Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 30, 2025Common StockMOption exerciseDisposed−21,472$0.00$040,270Direct
Jan 31, 2025Common StockMOption exerciseDisposed−22,346$0.00$017,924Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.9000 to $2.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.8000 to $1.8800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)